Connection

NANCY WEIGEL to Tumor Cells, Cultured

This is a "connection" page, showing publications NANCY WEIGEL has written about Tumor Cells, Cultured.
Connection Strength

0.925
  1. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget. 2015 Oct 13; 6(31):31997-2012.
    View in: PubMed
    Score: 0.104
  2. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014 Sep; 54:49-59.
    View in: PubMed
    Score: 0.095
  3. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids. 2013 Jun; 78(6):548-54.
    View in: PubMed
    Score: 0.086
  4. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007 Aug; 65(8 Pt 2):S116-7.
    View in: PubMed
    Score: 0.059
  5. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 01; 64(4):362-72.
    View in: PubMed
    Score: 0.052
  6. 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate. 2004 May 15; 59(3):282-91.
    View in: PubMed
    Score: 0.047
  7. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate. 2003 Sep 01; 56(4):293-304.
    View in: PubMed
    Score: 0.045
  8. The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific. Steroids. 2013 Jun; 78(6):542-7.
    View in: PubMed
    Score: 0.043
  9. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology. 2003 Jan; 144(1):50-60.
    View in: PubMed
    Score: 0.043
  10. Vector-averaged gravity-induced changes in cell signaling and vitamin D receptor activity in MG-63 cells are reversed by a 1,25-(OH)2D3 analog, EB1089. Bone. 2002 Sep; 31(3):381-8.
    View in: PubMed
    Score: 0.042
  11. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000 Feb 15; 60(4):779-82.
    View in: PubMed
    Score: 0.035
  12. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology. 2000 Jan; 141(1):10-7.
    View in: PubMed
    Score: 0.035
  13. Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol. 1997 Jun; 11(6):823-32.
    View in: PubMed
    Score: 0.029
  14. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997 Apr; 138(4):1491-7.
    View in: PubMed
    Score: 0.029
  15. Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem. 1994 Dec 09; 269(49):31034-40.
    View in: PubMed
    Score: 0.024
  16. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol. 2013 Jan; 42(1):35-43.
    View in: PubMed
    Score: 0.021
  17. Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol. 1992 Oct; 6(10):1585-97.
    View in: PubMed
    Score: 0.021
  18. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids. 2006 Feb; 71(2):102-15.
    View in: PubMed
    Score: 0.013
  19. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol. 2005 Feb; 25(3):1054-69.
    View in: PubMed
    Score: 0.012
  20. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27.
    View in: PubMed
    Score: 0.012
  21. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol. 2003 Apr; 169(4):1553-7.
    View in: PubMed
    Score: 0.011
  22. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate. 2001 Nov 01; 49(3):224-33.
    View in: PubMed
    Score: 0.010
  23. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst. 2001 Sep 05; 93(17):1314-24.
    View in: PubMed
    Score: 0.010
  24. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol. 2000 Jan; 14(1):52-65.
    View in: PubMed
    Score: 0.009
  25. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Mol Cell. 1999 Apr; 3(4):521-6.
    View in: PubMed
    Score: 0.008
  26. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol. 1998 Mar; 18(3):1369-78.
    View in: PubMed
    Score: 0.008
  27. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem. 1996 Jan 12; 271(2):1209-17.
    View in: PubMed
    Score: 0.007
  28. 1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. Biochemistry. 1994 Apr 12; 33(14):4300-11.
    View in: PubMed
    Score: 0.006
  29. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci U S A. 1993 May 15; 90(10):4441-5.
    View in: PubMed
    Score: 0.005
  30. Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res Treat. 1993; 27(1-2):41-56.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.